Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$63.47 ▼ -0.49
(-0.77%)
MKT CAP: $5.63B • VOL: 782.7K
52W L $36 52W H $81
CGON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$190.8M | -$114.7M | -$55.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$161.0M | -$88.0M | -$48.6M |
| EBITDA (Normalized) | -$190.7M | -$114.5M | -$55.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$132.3M | -$78.7M | -$45.7M |
| Capital Expenditures (CapEx) | $134.0K | $234.0K | $0 |
| Free Cash Flow (FCF) | -$132.5M | -$78.9M | -$45.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -20.8% | -19.0% | -2.3% |
| Cash & Short-Term Equivalents | $32.5M | $257.1M | $340.4M |
| Total Debt (Short + Long Term) | $3.0M | $0 | $724.1M |
| Total Stockholders' Equity | $752.6M | $733.4M | $1.49B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CGON.